Tefferi Tefferi: Influence Statistics

Tefferi Tefferi

Tefferi Tefferi

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA | Mayo Clinic, Rochester, Minnesota, United States. | Division of Hematology, ...

Tefferi Tefferi: Expert Impact

Concepts for which Tefferi Tefferi has direct influence: Essential thrombocythemia , Primary myelofibrosis , Polycythemia vera , Myeloproliferative neoplasms , Myeloid metaplasia , Bone marrow , Janus kinase .

Tefferi Tefferi: KOL impact

Concepts related to the work of other authors for which for which Tefferi Tefferi has influence: Myelodysplastic syndromes , Myeloproliferative neoplasms , Essential thrombocythemia , Polycythemia vera , Janus kinase , Acute myeloid leukemia , Bone marrow .

KOL Resume for Tefferi Tefferi

Year
2022

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

Mayo Clinic, Rochester, Minnesota, United States.

2021

Mayo Clinic of Rochester, Rochester, MN, USA

Division of Hematology, Department of Medicine, and

2020

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Mayo Clinic Cancer Center, Rochester, MN;

2019

Mayo Clinic, Rochester, MN;

2018

Divisions of Hematology, Departments of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

Ayalew Tefferi, Mayo Clinic, Rochester, MN; Paola Guglielmelli, University of Florence, Florence, Italy; Terra L. Lasho, Naseema Gangat, Rhett P. Ketterling, and Animesh Pardanani, Mayo Clinic, Rochester, MN; and Alessandro M. Vannucchi, University of Florence, Florence, Italy.

Department of Hematology, Mayo Clinic, Rochester, Minnesota

2017

Hematology division, Mayo Clinic, Rochester, Minnesota

Paola Guglielmelli, Giada Rotunno, Carmela Mannarelli, Annalisa Pacilli, Francesco Mannelli, and Alessandro M. Vannucchi, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence; Elisa Rumi, Vittorio Rosti, Giovanni Barosi, and Mario Cazzola, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo; Elisa Rumi and Mario Cazzola, University of Pavia, Pavia; Alessandro Rambaldi, University of Milan, Milan; Alessandro Rambaldi and Tiziano Barbui, Azienda Socio sanitaria Territoriale Papa Giovanni XXIII, Bergamo; Francesco Passamonti, University of Insubria, Varese, Italy; and Terra L. Lasho, Mythri Mudireddy, Maura Nicolosi, Animesh Pardanani, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, and Ayalew Tefferi, Mayo Clinic, Rochester, MN.

Department of Internal Medicine Mayo Clinic Rochester MN USA

2016

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA;

Department of Medicine, Mayo Clinic, Rochester, Minnesota.

Hematology, Mayo Clinic College of Medicine, Rochester, MN.

MAYO CLINIC.

Mayo Clinic, Rochester, MN

Prominent publications by Tefferi Tefferi

KOL-Index: 17364 . PURPOSE: The Dynamic International Prognostic Scoring System (DIPSS) for primary myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years, hemoglobin lower than 10 g/dL, leukocytes higher than 25 × 10(9)/L, circulating blasts ≥ 1%, and constitutional symptoms. The main objective of this study was to refine DIPSS by incorporating prognostic information from ...
Known for Platelet Count | Primary Myelofibrosis | Transfusion Status | Unfavorable Karyotype
KOL-Index: 17309 . OBJECTIVE: To evaluate the efficacy of rituximab for the treatment of adult patients with immune cytopenia, including idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, and Evans syndrome. PATIENTS AND METHODS: We retrospectively reviewed the medical charts of all patients treated with rituximab for immune cytopenia at the Mayo Clinic in Rochester, Minn, through ...
Known for Evans Syndrome | Autoimmune Hemolytic Anemia | Rituximab Treatment | Monoclonal Antibodies
KOL-Index: 17046 . Myeloproliferative neoplasms (MPNs) originate from genetically transformed hematopoietic stem cells that retain the capacity for multilineage differentiation and effective myelopoiesis. Beginning in early 2005, a number of novel mutations involving Janus kinase 2 (JAK2), Myeloproliferative Leukemia Virus (MPL), TET oncogene family member 2 (TET2), Additional Sex Combs-Like 1 (ASXL1), ...
Known for Tet2 Asxl1 | Myeloproliferative Neoplasms | Janus Kinase Jak2 | Mpl Mutations
KOL-Index: 16333 . DISEASE OVERVIEW: Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. DIAGNOSIS: PV is defined by a JAK2 mutation, whose ...
Known for Essential Thrombocythemia | Polycythemia Vera | Mpl Mutations | Cytoreductive Therapy
KOL-Index: 15500 . OBJECTIVE: Hematopoietic stem cell transplant (HSCT) recipients admitted to the intensive care unit (ICU) have high mortality. The prognostic importance of peripheral blood stem cell source in critically ill HSCT recipients and the performance of Acute Physiology and Chronic Health Evaluation (APACHE) III have not been well studied. In a previous study, the hospital mortality rate of HSCT ...
Known for Acute Physiology | Stem Cell | Chronic Health Evaluation | Icu Mortality
KOL-Index: 15213 . DISEASE OVERVIEW: Ring sideroblasts (RS) are erythroid precursors with abnormal perinuclear mitochondrial iron accumulation. Two myeloid neoplasms defined by the presence of RS, include refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T). DIAGNOSIS: RARS is a lower risk myelodysplastic syndrome (MDS) with dysplasia limited to the erythroid lineage, <5% ...
Known for Refractory Anemia | Ring Sideroblasts | Rars Thrombocytosis | Presence Bm
KOL-Index: 14881 . Autologous stem cell transplantation (ASCT) improves survival in patients with previously untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non-Hodgkin lymphoma (NHL). Lower relapse rates seen in allogeneic stem cell transplantation have been related to early absolute lymphocyte count (ALC) recovery as a manifestation of early graft-verus-tumor effect. In ...
Known for Patients Alc | Superior Survival | 500 Cells Microl | Lymphocyte Recovery
KOL-Index: 14368 . BACKGROUND: Idiopathic hypereosinophilic syndrome involves a prolonged state of eosinophilia associated with organ dysfunction. It is of unknown cause. Recent reports of responses to imatinib in patients with the syndrome suggested that an activated kinase such as ABL, platelet-derived growth factor receptor (PDGFR), or KIT, all of which are inhibited by imatinib, might be the ...
Known for Hypereosinophilic Syndrome | Tyrosine Kinase | Therapeutic Target | Fip1l1 Gene
KOL-Index: 13945 . Gain-of-function mutations of the receptor tyrosine kinase KIT play a key role in the pathogenesis of systemic mastocytosis (SM), gastrointestinal stromal tumors (GISTs), and some cases of acute myeloid leukemia (AML). Whereas KIT juxtamembrane domain mutations seen in most patients with GIST are highly sensitive to imatinib, the kinase activation loop mutant D816V, frequently encountered ...
Known for D816v Mutation | Mast Cells | Tyrosine Kinase | Phosphorylation Kit
KOL-Index: 13733 . The adenosine triphosphate binding-site-directed agent STI571 and the tyrphostin adaphostin are undergoing evaluation as bcr/abl kinase inhibitors. The current study compared the effects of these agents on the survival of K562 cells, bcr/abl-transduced FDC-P1 cells, and myeloid progenitors from patients with chronic myelogenous leukemia (CML) compared with healthy donors. Treatment of K562 ...
Known for Leukemia Cells | Chronic Myelogenous | Bcr Abl | Kinase Inhibitors
KOL-Index: 13646 . DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis. Other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation. DIAGNOSIS: PV is defined by a JAK2 mutation, whose ...
Known for Polycythemia Vera | Essential Thrombocythemia | Risk Thrombosis | Extreme Thrombocytosis
KOL-Index: 13519 . DISEASE OVERVIEW: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and myeloproliferative neoplasms, with an inherent risk for leukemic transformation (∼15%-20% over 3-5 years). DIAGNOSIS: Diagnosis is based on the presence of sustained (>3 months) peripheral blood monocytosis (≥1 × 109 /L; monocytes ...
Known for Risk Stratification | Chronic Myelomonocytic Leukemia | Mmm Asxl1 Mutations | Diagnosis Presence
KOL-Index: 13477 . SRSF2, SF3B1, and U2AF35 (U2AF1) are the three most frequent genes involved with spliceosome mutations in myeloid malignancies. SF3B1 mutations are most frequent (~80%) in myelodysplastic syndromes (MDS) with ring sideroblasts (RS) but lack prognostic relevance. SRSF2 mutations are associated with shortened overall (OS) and leukemia-free survival (LFS) in both MDS and myelofibrosis. In ...
Known for Spliceosome Mutations | Myelomonocytic Leukemia | Cell Transformation | Prognostic Relevance
KOL-Index: 13207 . PURPOSE: Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development of MPN-directed therapies. We aimed to assess the utility of an abbreviated symptom score for the most pertinent and representative MPN symptoms for subsequent serial use in assessing response to therapy. PATIENTS AND ...
Known for Myeloproliferative Neoplasm | Symptom Score | Mpnsaf Tss | Patients Mpns

Key People For Essential Thrombocythemia

Top KOLs in the world
#1
Tefferi Tefferi
essential thrombocythemia primary myelofibrosis polycythemia vera
#2
Tiziano Barbui
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#3
Guido Finazzi
polycythemia vera essential thrombocythemia myeloproliferative neoplasms
#4
Alessandro Maria Vannucchi
speakers bureau board directors polycythemia vera
#5
Claire N Harrison
speakers bureau board directors advisory committees
#6
Francesco Passamonti
speakers bureau polycythemia vera board directors

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA | Mayo Clinic, Rochester, Minnesota, United States. | Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN USA | Division of Hematology